Our findings provide strong support for current guideline recommendations by the American Diabetes Association (ADA), European Society of Cardiology (ESC), and Kidney Disease: Improving Global Outcomes (KDIGO), all of which endorse SGLT2 inhibitors as first-line therapy in T2DM patients with heart failure or established cardiovascular disease [21,22]. This evidence concerns the gene SLC5A2 and heart failure.